Last updated on October 2018

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)


Brief description of study

Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a consistent reduction in blood eosinophil counts is observed in association with mepolizumab administration, with concomitant clinical improvement. This is a 32-week treatment period, randomized, double-blind, placebo-controlled, parallel group, multicentre study of mepolizumab in adolescent and adult subjects with severe HES receiving standard of care (SoC) therapy. This study will demonstrate the efficacy of mepolizumab compared with placebo based on maintenance of control of HES symptoms during the treatment period. The study will comprise of a screening period of up to approximately 4 weeks followed by a 32-Week study treatment period (subjects will be randomized 1:1 to placebo or mepolizumab) and up to 8-week additional follow-up period (12 weeks after the last dose of study treatment).

Clinical Study Identifier: NCT02836496

Contact Investigators or Research Sites near you

Start Over

GSK Investigational Site

Rochester, MN United States
  Connect »

GSK Investigational Site

Salt Lake City, UT United States
  Connect »

GSK Investigational Site

Toulouse Cedex 9, France
  Connect »

GSK Investigational Site

Kirchheim -Teck, Germany
  Connect »

GSK Investigational Site

Saint-Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Pozuelo (Madrid), Spain
  Connect »

GSK Investigational Site

Leicester, United Kingdom
  Connect »

GSK Investigational Site

Mar del Plata, Argentina
  Connect »

GSK Investigational Site

Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Moscow, Russian Federation
  Connect »

GSK Investigational Site

St Petersburg, Russian Federation
  Connect »

GSK Investigational Site

New Haven, CT United States
  Connect »

GSK Investigational Site

Charleston, SC United States
  Connect »

GSK Investigational Site

Cincinnati, OH United States
  Connect »

GSK Investigational Site

San Diego, CA United States
  Connect »

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Mayfield Heights, OH United States
  Connect »

GSK Investigational Site

Santo André - SP, Brazil
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.